APRE Shares Outstanding History
Below is a table of the APRE shares outstanding history going back to 10/3/2019:

Date APRE Shares Outstanding

Also see: APRE Market Cap History
APRE Historical Shares Outstanding:
+38.67% CAGR
APRE Historical Shares Outstanding: +38.67% CAGR

Mouse over chart for data details
10/3/2019 ...11/9/2022
Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, a mutated gene in cancer. Co.'s main product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia. Co. is conducting several trials in hematologic malignancy indications, including a trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS. We show 15 historical shares outstanding datapoints in our coverage of APRE's shares outstanding history.

Understanding the changing numbers of APRE shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like APRE versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching APRE by allowing them to research APRE shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree APRE Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aprea Therapeutics (APRE) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

APRI Shares Outstanding History
APTX Shares Outstanding History
APVO Shares Outstanding History
APYX Shares Outstanding History
AQST Shares Outstanding History
AQXP Shares Outstanding History
ARA Shares Outstanding History
ARAV Shares Outstanding History
ARAY Shares Outstanding History
ARCT Shares Outstanding History
More Healthcare companies »


APRE Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.